Bio News

Actimed has ended a technology transfer agreement valued at $126.2 million. With the termination, the company regained all rights to the wasting disease treatment S-oxprenolol. Actimed plans to begin clinical trials in amyotrophic lateral sclerosis (ALS) after completing chemistry, manufacturing and controls (CMC) activities.

BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882